Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways

Abstract Background Serotonin reuptake inhibitors (SSRIs) may impair platelet function. Thrombin is a strong platelet agonist causing irreversible aggregation, release of granules' contents, cytoskeletal rearrangement and activation of signalling pathways. We investigated the effects of the SSRI escitalopram (SCIT) on thrombin-induced platelet response. Methods Isolated platelets were exposed to SCIT and activated with thrombin. We evaluated (1) platelet response by aggregometry and flow cytometry; (2) modifications in cytoskeleton proteins and signalling pathways by electrophoresis and Western blot; and (3) ultrastructural changes in platelets by electron microscopy. Results SCIT inhibited platelet response to thrombin, measured as platelet aggregation and expression of activation markers CD62-P and CD63 from platelet granules. Platelet aggregation decreased in a dose-dependent manner, reaching statistical significance with SCIT ≥32 µg/mL (65.4 ± 6.8% vs. 77.7 ± 2.5% for controls; p < 0.05). Expression of activation markers was statistically reduced with SCIT ≥20 µg/mL (p < 0.05). SCIT impaired the polymerization of the actin cytoskeleton and association of contractile proteins during activation with thrombin (p < 0.05 with SCIT ≥50 µg/mL). Resting platelets incubated with SCIT became most spherical, with increased platelet roundness (p < 0.01, SCIT 50 µg/mL vs. control). SCIT interfered with signalling pathways modulated by thrombin (RhoA, PKC, Erk1/2 and PI3K/AKT). Conclusions Our data indicate that SCIT inhibits thrombin-induced platelet response and interferes with cytoskeletal assembly and related signalling pathways, thus resulting in compromised release of granules' contents, reduced platelet activation and aggregation. These mechanisms may explain the antithrombotic benefits observed in patients treated with this SSRI, and could become new therapeutic targets for future antithrombotic strategies.

[1]  U. Sambamoorthi,et al.  Use of selective-serotonin reuptake inhibitors and platelet aggregation inhibitors among individuals with co-occurring atherosclerotic cardiovascular disease and depression or anxiety , 2016, SAGE open medicine.

[2]  H. Heijnen,et al.  Platelet secretory behaviour: as diverse as the granules … or not? , 2015, Journal of thrombosis and haemostasis : JTH.

[3]  C. Nemeroff,et al.  The interface of depression and cardiovascular disease: therapeutic implications , 2015, Annals of the New York Academy of Sciences.

[4]  Deepak L. Bhatt,et al.  New approaches to inhibiting platelets and coagulation. , 2015, Annual review of pharmacology and toxicology.

[5]  I. López-Vílchez,et al.  Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment. , 2014, Journal of affective disorders.

[6]  A. Galán,et al.  Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. , 2013, Drugs of today.

[7]  H. Lane,et al.  Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. , 2013, Thrombosis research.

[8]  C. Humpel,et al.  Platelets in psychiatric disorders. , 2012, World journal of psychiatry.

[9]  O. Forlenza,et al.  Platelet biomarkers in Alzheimer's disease. , 2012, World journal of psychiatry.

[10]  D. Ben-shachar,et al.  Platelets: A possible glance into brain biological processes in schizophrenia. , 2012, World journal of psychiatry.

[11]  C. Andrade.  Drug interactions in the treatment of depression in patients with ischemic heart disease. , 2012, The Journal of clinical psychiatry.

[12]  Shuchi Gupta,et al.  Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. , 2012, Blood.

[13]  E. Domenici,et al.  Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge. , 2011, The international journal of neuropsychopharmacology.

[14]  F. Abajo.  Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function , 2011 .

[15]  H. Lane,et al.  A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. , 2010, Thrombosis research.

[16]  Gemma Vilahur,et al.  Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. , 2010, European heart journal.

[17]  I. López-Vílchez,et al.  Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake. , 2009, Cardiovascular research.

[18]  I. López-Vílchez,et al.  Serotonergic mechanisms enhance platelet-mediated thrombogenicity , 2009, Thrombosis and Haemostasis.

[19]  E. Hodneland,et al.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner , 2009, Journal of chemical biology.

[20]  F. Lotufo-Neto,et al.  Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline , 2009, Journal of hypertension.

[21]  E. Hodneland,et al.  Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane? , 2008, Biochimica et biophysica acta.

[22]  J Thomas Bigger,et al.  Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdiscip , 2008, Circulation.

[23]  E. Cook,et al.  Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. , 2008, The Journal of clinical investigation.

[24]  N. Frasure-smith,et al.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. , 2007, JAMA.

[25]  M. Esler,et al.  Sympathetic Activity in Major Depressive Disorder: Identifying Those at Increased Cardiac Risk? , 2007, Journal of hypertension.

[26]  Stefan Offermanns,et al.  Activation of Platelet Function Through G Protein–Coupled Receptors Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease In Vivo Thrombus Formation Platelet Adhesion Platelet Inhibitors and Thrombus Formation , 2006 .

[27]  S. Kunapuli,et al.  P2Y12 receptor‐mediated potentiation of thrombin‐induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation , 2006, Journal of thrombosis and haemostasis : JTH.

[28]  M. Díaz-Ricart,et al.  Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk. , 2005, Drugs of today.

[29]  R. Carney,et al.  Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. , 2005, Archives of general psychiatry.

[30]  R. Urso,et al.  Activity of Citalopram on Adenosine and Serotonin Circulating Levels in Depressed Patients , 2005, Journal of clinical psychopharmacology.

[31]  M. Díaz-Ricart,et al.  Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein Ib , 2005, Platelets.

[32]  C. O'connor,et al.  Depression as a risk factor for post-MI mortality. , 2004, Journal of the American College of Cardiology.

[33]  E. Maurer-Spurej,et al.  The influence of selective serotonin reuptake inhibitors on human platelet serotonin , 2003, Thrombosis and Haemostasis.

[34]  M. Bryckaert,et al.  Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf‐1 or B‐Raf , 2002, FEBS letters.

[35]  R. Califf,et al.  Sertraline treatment of major depression in patients with acute MI or unstable angina , 2002, European Neuropsychopharmacology.

[36]  M. Díaz-Ricart,et al.  TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural features. , 2002, The American journal of pathology.

[37]  C. O'connor,et al.  Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. , 2001, Pharmacological research.

[38]  H. Eichler,et al.  Paroxetine decreases platelet serotonin storage and platelet function in human beings , 2000, Clinical pharmacology and therapeutics.

[39]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[40]  M. Díaz-Ricart,et al.  Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method , 2000, Transfusion.

[41]  S. Yamawaki,et al.  Chronic treatment with antidepressants, verapamil, or lithium inhibits the serotonin-induced intracellular calcium response in individual C6 rat glioma cells. , 1997, Life sciences.

[42]  Y. Okamoto,et al.  Effect of citalopram on the desensitization of serotonin-2A receptor-mediated calcium mobilization in rat glioma cells , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[43]  B. Payrastre,et al.  Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase , 1995, The Journal of cell biology.

[44]  R. Grant,et al.  Nonreversible loss of platelet aggregability induced by calcium deprivation. , 1978, Blood.

[45]  A. Kauskot,et al.  Platelet receptors. , 2012, Handbook of experimental pharmacology.

[46]  F. D. de Abajo,et al.  Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function , 2011, Drugs & aging.

[47]  J. White,et al.  EDTA induced changes in platelet structure and function: influence on particle uptake. , 1999, Platelets.

[48]  P. Bongioanni,et al.  Human blood platelet as research tool in neuropsychopharmacology. , 1991, Journal of neural transmission. Supplementum.